Gentian Diagnostics ASFRA:6FK +3.58%73 Interest Coverage is 7.33 as of Jun. 2026, which is 81% below its 10-year median of 37.87. GuruFocus rates FRA:6FK with a GF Score™ of 73/100 and a GF Value™ of €5.19 (Significantly Undervalued). Among 466 Medical Devices & Instruments companies, Gentian Diagnostics AS ranks worse than 214592.06% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Gentian Diagnostics AS's
Operating Income
for the
three
months ended in Jun. 2026 was €0.54 Mil. Gentian Diagnostics AS's Interest Expense for the
three
months ended in Jun. 2026 was €-0.07 Mil.
Gentian Diagnostics AS's interest coverage for the quarter that ended in Jun. 2026 was 7.33.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Gentian Diagnostics AS's Interest Coverage or its related term are showing as below:
FRA:6FK's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 16.05 * Ranked among companies with meaningful Interest Coverage only.
Gentian Diagnostics AS (FRA:6FK) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Gentian Diagnostics AS Interest Coverage Related Terms
Gentian Diagnostics AS Interest Coverage Historical Data
* Premium members only.
The historical data trend for Gentian Diagnostics AS's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:6FK vs ABT, SYK, MDT: Interest Coverage Comparison
For the Medical Devices subindustry, Gentian Diagnostics AS's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gentian Diagnostics AS Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Gentian Diagnostics AS's Interest Coverage falls into.
Gentian Diagnostics AS Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gentian Diagnostics AS (FRA:6FK) has a Interest Coverage of 7.33 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Gentian Diagnostics AS and its competitors. This is 81% below median its historical median of 37.87. According to the industry distribution chart, Gentian Diagnostics AS ranks #999999 out of 466 companies in the Medical Devices & Instruments industry.
Is Gentian Diagnostics AS's Interest Coverage too high?
Gentian Diagnostics AS's current Interest Coverage of 7.33 is 81% below median its 10-year median of 37.87. The Medical Devices & Instruments industry median Interest Coverage is 16.05. Gentian Diagnostics AS's value of 7.33 is 54.3% below this industry median. Based on the distribution chart, Gentian Diagnostics AS ranks #999999 out of 466 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Interest Coverage compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gentian Diagnostics AS ranks #999999 out of 466 companies for Interest Coverage. This places Gentian Diagnostics AS in the lower half of its industry. The industry median Interest Coverage is 16.05. Gentian Diagnostics AS's value of 7.33 is 54.3% below this benchmark. While the company's 10-year median is 37.87 vs. the industry median of 16.05, Gentian Diagnostics AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 16.05, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gentian Diagnostics AS's current Interest Coverage of 7.33 is 54.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Gentian Diagnostics AS and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gentian Diagnostics AS's current Interest Coverage is 7.33, which is 81% below median its own 10-year median of 37.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (FRA:6FK) is currently considered Significantly Undervalued. The stock's GF Value™ is €5.19, compared to a current price of €3.47 — trading 33.1% below its estimated fair value. The current Interest Coverage is 7.33, which is 81% below median its 10-year median of 37.87 and 54.3% below the Medical Devices & Instruments industry median of 16.05. Gentian Diagnostics AS's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Gentian Diagnostics AS (FRA:6FK), the current Interest Coverage is 7.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gentian Diagnostics AS (FRA:6FK) Overvalued in 2026?
Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued.
The current stock price of €3.47 is trading 33.1% below its estimated GF Value™ of €5.19.
GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.
Key valuation signals for FRA:6FK:
Interest Coverage: 7.33 (81% below median its 10-year median of 37.87)
GF Value™: €5.19 vs. price of €3.47 (33.1% below fair value)
Industry Position: 54.3% below the Medical Devices & Instruments median (#999999 of 466)
No single metric tells the full story. See the FRA:6FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
73GF Score
Get the complete analysis for FRA:6FK
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FK has been successfully added to your 
